MedImmune Breaks Ground on New Expansion
ePT--the Electronic Newsletter of Pharmaceutical Technology
MedImmune, Inc. has broken ground on an expansion to its biologics manufacturing facility in Frederick, Maryland. The $250-million expansion is the first phase of a multi-phase construction project that MedImmune announced last fall.
Gaithersburg, MD (Sept. 13) -MedImmune, Inc. (www.medimmune.com) has broken ground on an expansion to its biologics manufacturing facility in Frederick, Maryland. The $250-million expansion is the first phase of a multi-phase construction project that MedImmune announced last fall.
The company’s “Synagis” monoclonal antibody is currently produced at the facility, and the expansion will increase the cell-culture manufacturing production capacity in preparation for future monoclonal antibodies that are currently in development. MedImmune recently received a five-year contract worth $170-million from the United States Department of Health and Human Services (HHS, Washington, D.C., www.hhs.gov) to develop cell culture-based seasonal and pandemic vaccines. The vaccines will be produced at the Frederick facility.
MedImmune has purchased the raw materials and equipment needed for the expanded facility, and Beck, Powell & Parsons (Baltimore, MD, www.beckpowell.com) has been designated the architectural firm responsible for the project. The first phase of the expansion is expected to be complete in late 2009.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
